- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: OMP-21M18 | OMP21M18
Compound class: Antibody
Comment: Demcizumab is a humanised IgG2 monoclonal antibody targeting DLL4 (delta like canonical Notch ligand 4), a membrane bound Notch receptor ligand expressed predominantly on vascular endothelial cells.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain forming demcizumab reveals US7750124 B2 as the covering patent .
|No information available.|
|Summary of Clinical Use|
|Demcizumab was advanced to clinical trials in patients with advanced solid tumours (max phase 2). However, development appears to have been discontinued.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Epitope mapping reveals that demcizumab binds to an epitope within the DSL domain (Delta/Serrate/lag-2) of DLL4 . Demcizumab binds to DLL4 (delta like canonical Notch ligand 4) and prevents this ligand from activating receptors of the Notch signalling pathway. Notch pathway inhibition has anti-cancer effects.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02259582||A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer||Phase 2 Interventional||Mereo BioPharma||3|
|NCT00001693||Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers||Phase 1 Interventional||National Institutes of Health Clinical Center (CC)||1|